- Home
- Companies
- canada newfoundland
- biopsy testing
Show results for
Refine by
Biopsy Testing Suppliers Serving Canada Newfoundland
24 companies found
based inParis Cedex 06, FRANCE
We develop and commercialize patented, disruptive liquid biopsy tests – innovative blood tests in oncology – based on a unique cell isolation technology called ISET (Isolation by SizE of Tumor cells) and cyto-molecular profiling of Circulating Tumor ...
based inWest Lafayette, INDIANA (USA)
Tymora Analytical Operations provides diagnostic development and exosome proteomics contract services and products for improved cancer research. Tymora’s primary goal is to enable the shift from tissue to liquid biopsy. Our new technologies allow ...
based inWaltham, MASSACHUSETTS (USA)
Exosome Diagnostics, Inc. is commercializing minimally invasive molecular diagnostics in blood and urine to enable doctors to select optimal therapies for cancer and other diseases. Exosomes are lipid bilayer covered microvesicles shed by solid ...
The only exosome-based test that provides unique, actionable intelligence to help you decide if biopsy is necessary; independent of PSA and other standard of care (SOC) features. Connect with a representative in ...
based inFrankfurt, GERMANY
NeraCare develops and commercializes molecular diagnostic tests for patients with skin cancer. The tests provide actionable, tumor-specific information for each individual patient. The information is used to make improved treatment decisions, i.e. ...
From the moment melanoma is diagnosed, your patient depends on you to recommend the best course of action. Hovever, it is important to remember that no two melanoma patients or their tumors are alike.The MELAGENIX test provides a genomic-based, ...
based inAlameda, CALIFORNIA (USA)
Fluxion delivers advanced solutions that transform complex cell-based and cell-free assays. Leading labs across the globe rely on Fluxion's instruments, kits, and lab services to research novel biology, accelerate drug discovery, and tailor ...
Fluxion provides analytical services for a diverse range of liquid biopsy and CTC applications. Our Lab Services programs enables you to get results quickly and efficiently using Fluxion’s state-of-the-art technology and laboratory facilities. ...
based inCambridge, UNITED KINGDOM
Owlstone Medical is developing a breathalyzer for disease. With a goal to find ways to improve non-invasive diagnostics for respiratory diseases, liver diseases, cancer, digestive health and other conditions. Our mission is to save 100,000 lives and ...
Developing Breath Biopsy for clinical applications in early detection and precision ...
based inSyracuse, NEW YORK (USA)
Mesothelioma is an aggressive cancer that affects the lining of the lungs, heart, or abdomen. Caused by the inhalation of asbestos fibers, mesothelioma is often diagnosed in older individuals who worked with asbestos products. Prognosis for ...
based inMunich, GERMANY
ImevaX is a Biotech company based in Munich with a focus on facilitating H. pylori Diagnostics with a novel Rapid Diagnostic ...
based inValladolid, SPAIN
Founded in 2010, AMADIX is a leading molecular diagnostics company, focused on liquid biopsy, developing innovative diagnostic tests for early cancer detection in blood. Our mission is to extend people’s lives by developing disruptive technologies ...
It can also be used as a tool for a high-risk screening population in combination with Low Dose Computed Tomography (LDCT). DiagnoLung identifies and measures proteins which are differentially expressed in blood samples of individuals with Lung ...
based inRedwood City, CALIFORNIA (USA)
Guardant Health is a leading precision oncology company dedicated to helping conquer cancer through our proprietary blood tests, vast data sets, and advanced analytics. We’re developing blood tests for early detection in high-risk populations and ...
Our Guardant360® CDx test is FDA-approved for complete genomic testing across all solid cancers, providing doctors guideline-complete genomic results in 7 days from a simple blood draw to inform treatment ...
based inSeoul, SOUTH KOREA
We detect and analyze genomic profile of tumor DNA with a single draw of blood. With this comprehensive profile, we provide personalized and optimized analysis information that can be utilized in therapy selection and monitoring. Ultimately, we ...
AlphaLiquid® Detect is an industry-first tumor-informed, hybrid-capture NGS-based liquid biopsy test designed for MRD detection and recurrence monitoring in stage I-III solid tumor patients. The assay ...
based inBuccinasco (MI), ITALY
Villa Sistemi Medicali is following the path of a production based on high-tech, constant research and scientific development. Founded in 1958 by Mr. Alfio Villa and headquartered in Buccinasco (Italy), it started as a company committed to the ...
The completely redesigned Melody III mammography line is the best the new technologies and Villa’s experience in mammography can offer. Every aspect of the X-ray examination and every characteristic of the mammography unit have been reviewed ...
based inVillejuif, FRANCE
Stilla Technologies is the multiplex digital PCR company transforming complex genomic data into actionable insights across a wide range of research and clinical applications including cancer and liquid biopsy studies, cell and gene therapies, ...
based inNotting Hill, AUSTRALIA
INOVIQ Ltd (ASX:IIQ) (INOVIQ) is developing and commercialising an innovative portfolio of diagnostic and exosome-based solutions for the earlier detection, diagnosis, prognosis and monitoring of cancer and other diseases to improve patient outcomes ...
based inBoston, MASSACHUSETTS (USA)
SOPHiA GENETICS is the creator of a global data-sharing network – we work with customers from over 790 institutions in over 70 countries. Our network advances data-driven medicine to improve health outcomes and economics worldwide. We offer a ...
Pioneering Innovation, Streamlining Adoption: We are pushing the boundaries of today’s liquid biopsy capabilities. Bring liquid biopsy to your lab with our streamlined DNA-only NGS workflow, taking you from cell-free DNA sample to ...
based inSan Diego, CALIFORNIA (USA)
We are dedicated to one thing: improving outcomes for cancer patients. That’s why we focus on developing innovative diagnostic solutions that give patients and doctors the information they need—all from a simple blood test, known as a liquid biopsy. ...
Combining Biocept’s Liquid Biopsy biomarker testing expertise with Oncomine™ from Thermo Fisher Scientific’s next-generation sequencing and decision support ...
based inNew York, NEW YORK (USA)
miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management ...
The company’s proprietary miR Disease Management Platform® was developed to revolutionize the standard of value-based care for cancers and initially focuses on urological cancers. The initial test delivered by the miR ...
based inMarlborough, MASSACHUSETTS (USA)
Cytiva, now with the life sciences business from Pall, is a global provider of technologies, services, and expertise to help researchers and companies protect and preserve the planet for improved human health and safety. Our products offer quality, ...
based inPrinceton, NEW JERSEY (USA)
Cysview is a pharmaceutical product that makes non-muscle invasive bladder cancer tumors glow bright pink under blue light during a cystoscopy. Because the cancer is more visible, urologists can remove it more completely than if they weren’t using ...
A Transurethral Resection of Bladder Tumor (TURBT) is a procedure where a urologist removes tumors from the bladder wall. The procedure is performed using specialized instruments that are inserted through the urethra into the bladder. For the tumor ...
based inBerlin, GERMANY
We revolutionize the way of cancer diagnostics using our unique, proprietary DNA methylation biomarker technology. Epigenomics develops and commercializes patient-friendly, blood-based diagnostic tests across multiple cancer indications with high ...
Colorectal cancer is curable in about 90% of cases if detected early. Nevertheless, this disease is one of the most frequent causes of cancer-related deaths in the industrialized world. Regular screening can prevent colorectal cancer. Epi ...